Lachmann HJ, Goodman HJ, Gilbertson JA, Gallimore JR, Sabin CA, Gillmore JD, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med. 2007;356(23):2361–71. https://doi.org/10.1056/NEJMoa070265.

Article  CAS  PubMed  Google Scholar 

Papa R, Lachmann HJ. Secondary, AA, Amyloidosis. Rheum Dis Clin North Am. 2018;44(4):585–603. https://doi.org/10.1016/j.rdc.2018.06.004.

Article  PubMed  Google Scholar 

Hemminki K, Li X, Försti A, Sundquist J, Sundquist K. Incidence and survival in non-hereditary amyloidosis in Sweden. BMC Public Health. 2012;12:974. https://doi.org/10.1186/1471-2458-12-974.

Article  PubMed  PubMed Central  Google Scholar 

Aguirre MA, Boietti BR, Nucifora E, Sorroche PB, González Bernaldo de Quirós F, Giunta DH, et al. Incidence rate of amyloidosis in patients from a medical care program in Buenos Aires, Argentina: a prospective cohort. Amyloid. 2016;23(3):184–7. https://doi.org/10.1080/13506129.2016.1207626.

Karam S, Haidous M, Royal V, Leung N. Renal AA amyloidosis: presentation, diagnosis, and current therapeutic options: a review. Kidney Int. 2023;103(3):473–84. https://doi.org/10.1016/j.kint.2022.10.028.

Article  CAS  PubMed  Google Scholar 

Dasari S, Theis JD, Vrana JA, Rech KL, Dao LN, Howard MT, et al. Amyloid typing by mass spectrometry in clinical practice: a comprehensive review of 16,175 samples. Mayo Clin Proc. 2020;95(9):1852–64. https://doi.org/10.1016/j.mayocp.2020.06.029. A significant study addressing the clinical use of mass spectrometry in amyloidosis.

Article  CAS  PubMed  Google Scholar 

Real de Asúa D, Costa R, Galván JM, Filigheddu MT, Trujillo D, Cadiñanos J. Systemic AA amyloidosis: epidemiology, diagnosis, and management. Clin Epidemiol. 2014;6:369–77. https://doi.org/10.2147/clep.S39981.

Article  PubMed  PubMed Central  Google Scholar 

Bektas M, Koca N, Oguz E, Sari S, Dagci G, Ince B, et al. Characteristics and course of patients with AA amyloidosis: single centre experience with 174 patients from Turkey. Rheumatology (Oxford). 2024;63(2):319–28. https://doi.org/10.1093/rheumatology/kead465.

Article  PubMed  Google Scholar 

Delplanque M, Galicier L, Oziol E, Ducharme-Bénard S, Oksenhendler E, Buob D, et al. AA Amyloidosis secondary to primary immune deficiency: about 40 cases including 2 new French cases and a systematic literature review. J Allergy Clin Immunol Pract. 2021;9(2):745-52.e1. https://doi.org/10.1016/j.jaip.2020.09.023.

Article  CAS  PubMed  Google Scholar 

Lachmann HJ. Periodic fever syndromes. Best Pract Res Clin Rheumatol. 2017;31(4):596–609. https://doi.org/10.1016/j.berh.2017.12.001. A recent review of periodic fever syndromes that are known to result in AA amyloidosis if left untreated or undertreated.

Article  PubMed  Google Scholar 

Bunker D, Gorevic P. AA amyloidosis: Mount Sinai experience, 1997–2012. Mt Sinai J Med. 2012;79(6):749–56. https://doi.org/10.1002/msj.21342.

Article  PubMed  Google Scholar 

Blank N, Hegenbart U, Dietrich S, Brune M, Beimler J, Röcken C, et al. Obesity is a significant susceptibility factor for idiopathic AA amyloidosis. Amyloid. 2018;25(1):37–45. https://doi.org/10.1080/13506129.2018.1429391.

Article  CAS  PubMed  Google Scholar 

Westermark GT, Fändrich M, Westermark P. AA amyloidosis: pathogenesis and targeted therapy. Annu Rev Pathol. 2015;10:321–44. https://doi.org/10.1146/annurev-pathol-020712-163913.

Article  CAS  PubMed  Google Scholar 

Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003;349(6):583–96. https://doi.org/10.1056/NEJMra023144.

Article  CAS  PubMed  Google Scholar 

Benson MD, Buxbaum JN, Eisenberg DS, Merlini G, Saraiva MJM, Sekijima Y, et al. Amyloid nomenclature 2020: update and recommendations by the International Society of Amyloidosis (ISA) nomenclature committee. Amyloid. 2020;27(4):217–22. https://doi.org/10.1080/13506129.2020.1835263.

Article  CAS  PubMed  Google Scholar 

Sack GH Jr. Serum amyloid A (SAA) proteins. Subcell Biochem. 2020;94:421–36. https://doi.org/10.1007/978-3-030-41769-7_17.

Article  CAS  PubMed  Google Scholar 

Shah C, Hari-Dass R, Raynes JG. Serum amyloid A is an innate immune opsonin for Gram-negative bacteria. Blood. 2006;108(5):1751–7. https://doi.org/10.1182/blood-2005-11-011932.

Article  CAS  PubMed  Google Scholar 

Getz GS, Krishack PA, Reardon CA. Serum amyloid A and atherosclerosis. Curr Opin Lipidol. 2016;27(5):531–5. https://doi.org/10.1097/mol.0000000000000331.

Article  CAS  PubMed  Google Scholar 

Connolly M, Mullan RH, McCormick J, Matthews C, Sullivan O, Kennedy A, et al. Acute-phase serum amyloid A regulates tumor necrosis factor α and matrix turnover and predicts disease progression in patients with inflammatory arthritis before and after biologic therapy. Arthritis Rheum. 2012;64(4):1035–45. https://doi.org/10.1002/art.33455.

Article  CAS  PubMed  Google Scholar 

Malle E, Sodin-Semrl S, Kovacevic A. Serum amyloid A: an acute-phase protein involved in tumour pathogenesis. Cell Mol Life Sci. 2009;66(1):9–26. https://doi.org/10.1007/s00018-008-8321-x.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Uhlar CM, Whitehead AS. Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem. 1999;265(2):501–23. https://doi.org/10.1046/j.1432-1327.1999.00657.x.

Article  CAS  PubMed  Google Scholar 

Booth DR, Booth SE, Gillmore JD, Hawkins PN, Pepys MB. SAA1 alleles as risk factors in reactive systemic AA amyloidosis. Amyloid. 1998;5(4):262–5. https://doi.org/10.3109/13506129809007299.

Article  CAS  PubMed  Google Scholar 

Yilmaz E, Balci B, Kutlay S, Ozen S, Ertürk S, Oner A, et al. Analysis of the modifying effects of SAA1, SAA2 and TNF-alpha gene polymorphisms on development of amyloidosis in FMF patients. Turk J Pediatr. 2003;45(3):198–202.

PubMed  Google Scholar 

Sikora J, Kmochová T, Mušálková D, Pohludka M, Přikryl P, Hartmannová H, et al. A mutation in the SAA1 promoter causes hereditary amyloid A amyloidosis. Kidney Int. 2022;101(2):349–59. https://doi.org/10.1016/j.kint.2021.09.007.

Article  CAS  PubMed  Google Scholar 

Baba S, Masago SA, Takahashi T, Kasama T, Sugimura H, Tsugane S, et al. A novel allelic variant of serum amyloid A, SAA1 gamma: genomic evidence, evolution, frequency, and implication as a risk factor for reactive systemic AA-amyloidosis. Hum Mol Genet. 1995;4(6):1083–7. https://doi.org/10.1093/hmg/4.6.1083.

Article  CAS  PubMed  Google Scholar 

van der Hilst JC, Yamada T, Op den Camp HJ, van der Meer JW, Drenth JP, Simon A. Increased susceptibility of serum amyloid A 1.1 to degradation by MMP-1: potential explanation for higher risk of type AA amyloidosis. Rheumatology (Oxford). 2008;47(11):1651–4. https://doi.org/10.1093/rheumatology/ken371.

Article  CAS  PubMed  Google Scholar 

Lu J, Yu Y, Zhu I, Cheng Y, Sun PD. Structural mechanism of serum amyloid A-mediated inflammatory amyloidosis. Proc Natl Acad Sci U S A. 2014;111(14):5189–94. https://doi.org/10.1073/pnas.1322357111.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bansal A, Schmidt M, Rennegarbe M, Haupt C, Liberta F, Stecher S, et al. AA amyloid fibrils from diseased tissue are structurally different from in vitro formed SAA fibrils. Nat Commun. 2021;12(1):1013. https://doi.org/10.1038/s41467-021-21129-z.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pepys MB. Amyloidosis. Annu Rev Med. 2006;57:223–41. https://doi.org/10.1146/annurev.med.57.121304.131243.

Article  CAS  PubMed  Google Scholar 

Gharibyan AL, Zamotin V, Yanamandra K, Moskaleva OS, Margulis BA, Kostanyan IA, et al. Lysozyme amyloid oligomers and fibrils induce cellular death via different apoptotic/necrotic pathways. J Mol Biol. 2007;365(5):1337–49. https://doi.org/10.1016/j.jmb.2006.10.101.

Article  CAS  PubMed  Google Scholar 

Migita K, Agematsu K, Masumoto J, Ida H, Honda S, Jiuchi Y, et al. The contribution of SAA1 polymorphisms to Familial Mediterranean fever susceptibility in the Japanese population. PLoS ONE. 2013;8(2):e55227. https://doi.org/10.1371/journal.pone.0055227.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Papa R, Doglio M, Lachmann HJ, Ozen S, Frenkel J, Simon A, et al. A web-based collection of genotype-phenotype associations in hereditary recurrent fevers from the Eurofever registry. Orphanet J Rare Dis. 2017;12(1):167. https://doi.org/10.1186/s13023-017-0720-3.

Article  PubMed  PubMed Central  Google Scholar 

Atoyan S, Hayrapetyan H, Sarkisian T, Ben-Chetrit E. MEFV and SAA1 genotype associations with clinical features of familial Mediterranean fever and amyloidosis in Armenia. Clin Exp Rheumatol. 2016;34(6 Suppl 102):72–6.

PubMed  Google Scholar 

Touitou I, Sarkisian T, Medlej-Hashim M, Tunca M, Livneh A, Cattan D, et al. Country as the primary risk factor for renal amyloidosis in familial Mediterranean fever. Arthritis Rheum. 2007;56(5):1706–12. https://doi.org/10.1002/art.22507.

Article  PubMed